Ascletis to Start China Phase III Trial of FASN Inhibitor for Brain Cancer
July 23, 2021 at 05:08 AM EDT
Ascletis Pharma of Hangzhou announced that its China Phase III trial of ASC40 combined with bevacizumab was approved for patients with recurrent glioblastoma (rGBM). ASC40 is an oral small molecule inhibitor of FASN. Ascletis acquired China rights to ASC40 from San Francisco 's 3-V Biosciences for NASH in 2019. In a Phase II trial, the combination therapy produced an overall response rate of 65% with a 20% complete response rate in patients with recurrent glioblastoma. More details.... Stock Symbol: (HK: 1672) Share this with colleagues: // //
